

 **#CARDIOTOX** **CARDIOTOX.ES**

CARDIOTOX 26

12-13 NOVEMBER

MADRID



VENUE

Meeting Place Castellana 81, Madrid

Thursday, 12th November

08:50 – 09:00

Welcome & Inauguration

Teresa López-Fernández, Cardiologist, Madrid
Raúl Córdoba, Hematologist, Madrid
Isabel Rodríguez, Radiation oncologist, Madrid
Álvaro Pinto, Medical oncologist, Madrid

09:00 – 09:35

TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE

Chairs:

Javier de Castro, Medical oncologist, Madrid
Raúl Córdoba, Hematologist, Madrid
Isabel Rodríguez, Radiation oncologist, Madrid

09:00 – 09:10

Cardio-oncology 2026: key advances for the clinic

09:10 – 09:25

Teresa López-Fernández, Cardiologist, Madrid

Proton therapy: is the heart still at risk?

Marianne Aznar, Radiation Oncology Physics, Manchester

09:25 – 09:35

Discussion

09:35 – 10:30

FROM BENCH TO BEDSIDE

Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events

Chairs:

Carlo Gabriele Tocchetti, Cardiologist, Naples
Virginia Calvo, Medical oncologist, Madrid

09:35 – 09:45

Mechanisms of ICI-related myotoxicity

Pilar Martín, Biologist, Madrid

09:45 – 09:55

ICI myotoxicity: from mechanisms to targeted treatment

Joe-Elie Salem, Cardiologist, Paris

09:55 – 10:05

Translational biomarkers in immune-related cardiotoxicity: from inflammatory cells to risk stratification

María Rosaria Galdiero, Clinical immunologist, Naples

10:05 – 10:15

T cell-based cancer therapies and associated cardiac irAEs

Lorenz Lehmann, Cardiologist, Heidelberg

10:15 – 10:30

Discussion

10:30 – 11:00

Coffee break

11:00 – 11:45

MEET THE EXPERTS

Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance

Chairs:

Virginia Calvo, Medical oncologist, Madrid

Pedro Moliner, Cardiologist, Barcelona

11:00 – 11:10

ICI rechallenge after myotoxicity: time for reassessment?

Joe-Elie Salem, Cardiologist, Paris

11:10 – 11:20

EGFR-targeted therapies: cardiovascular toxicity and monitoring

Oliver Higuera, Medical oncologist, Madrid

11:20 – 11:30

ALK inhibitors: practical surveillance and metabolic management

Dolores Isla, Medical oncologist, Zaragoza

11:30 – 11:45

Discussion

11:45 – 12:30

IN FOCUS

Tyrosine kinase inhibitors in CML: balancing vascular risk and efficacy

Chairs:

Valentín García, Hematologist, Madrid

Marta Fanlo Maresma, Internal Medicine, Barcelona

11:45 – 12:00

Advances in CML treatment

Natalia de las Heras, Hematologist, León

12:00 – 12:30

Panel discussion. Balancing vascular risk and efficacy in patients with CML

Raquel de Paz, Hematologist, Madrid

Pilar Agudo, Cardiologist, Madrid

Juan Pedro Justel, General practitioner, Madrid

12:30 – 13:30

CARDIAC IMAGING IN CARDIO-ONCOLOGY

From findings to decisions

Chairs:

Victoria Delgado, Cardiologist, Barcelona

Pilar Zamora, Medical oncologist, Madrid

12:30 – 12:40 How imaging in cardio-oncology has changed over the last decade

Dolores Mesa, Cardiologist, Córdoba

12:40 – 12:50 GLS drop: treat or observe?

Belén Terol, Cardiologist, Madrid

12:50 – 13:00 CMR: When does it alter therapy?

Rocío Eiros, Cardiologist, Salamanca

13:00 – 13:10 CMR in suspected ICI-myocarditis: diagnostic thresholds and pitfalls

Chiara Bucciarelli-Ducci, Cardiologist, London

13:10 – 13:20 Asymptomatic ASCVD in cancer survivorship: what next?

Inés García Lunar, Cardiologist, Madrid

13:20 – 13:30 Discussion

13:30 – 15:30 [Lunch break: Tutorials / Satellite Symposium](#)

15:30 – 16:30 **FROM BENCH TO BEDSIDE**

**The vicious cycle of cancer therapy-induced cardiac injury:
mechanisms and treatment windows**

Chairs:

Lorenz Lehmann, Cardiologist, Heidelberg

Inés García Lunar, Cardiologist, Madrid

15:30 – 15:40 Anthracycline cardiotoxicity: molecular mechanisms that inform prevention

Alessandra Ghigo, Cardiologist, Torino

15:40 – 15:50 Exercise in CTRCD: mechanistic rationale and treatment windows

Carlo Gabriele Tocchetti, Cardiologist, Naples

15:50 – 16:00 Neurohormonal inhibition in CTRCD: preclinical and clinical evidence

Pietro Ameri, Cardiologist, Genoa

16:00 – 16:10 Reversible vs irreversible CTRCD: biological continuum or distinct entities?

Dimitrios Farmakis, Cardiologist, Athens

16:10 – 16:30 Discussion

16:30 – 17:15	CARDIAC IMAGING IN CARDIO-ONCOLOGY Smarter cardiac imaging pathways for patient-centred cardio-oncology care Chairs: Chiara Bucciarelli-Ducci , Cardiologist, London
16:30 – 16:40	Clinical case presentation: why imaging workflows are now a bottleneck in cardio-oncology Silvia Valbuena , Cardiologist, Madrid
16:40 – 16:50	Echocardiography workflows: prioritisation, standardisation and AI implementation Victoria Delgado , Cardiologist, Barcelona
16:50 – 17:00	CMR workflows: selecting the right patients and delivering actionable answers Santo Dellegrottaglie , Cardiologist, Naples
17:00 – 17:15	Panel discussion: what should an efficient cardio-oncology imaging pathway look like?

17:15 – 18:30	CLINICAL CASE FORUM Acute cardio-oncology: are we ready for the 24-hour challenge? Chairs: Eduardo Zatarain , Cardiologist, Madrid Pietro Ameri , Cardiologist, Genoa Antonia Sambola , Cardiologist, Barcelona
17:15 – 17:30	ICI-myotoxicity: early signals and grey zones Jorge Álvarez Troncoso , Internal Medicine, Madrid
17:30 – 17:45	Acute coronary syndrome during cancer treatment Pedro Moliner , Cardiologist, Barcelona
17:45 – 18:00	Cardiovascular complications of CRS in CAR-T therapy Annamaria Brioli , Hematologist, Hannover
18:00 – 18:15	Acute pulmonary embolism in cancer: when to escalate Sandra Rosillo , Cardiologist, Madrid
18:15 – 18:30	Discussion

Friday, 13th November

08:15 – 09:00

SYMPOSIUM

Cardiovascular risk across cancer therapies and survivorship

Chairs:

Peter van der Meer, Cardiologist, Groningen

Cristina Mitroi, Cardiologist, Madrid

08:15 – 08:25

Cardiovascular risk with immunotherapy-based combinations

Diego Jiménez Bou, Medical oncologist, Madrid

08:25 – 08:35

Endocrine and targeted therapies in breast cancer: the unresolved long-term cardiovascular burden

Jutta Bergler-Klein, Cardiologist, Vienna

08:35 – 08:45

Biomarkers for risk stratification and long-term surveillance

Daniela Cardinale, Cardiologist, Milan

08:45 – 09:00

Discussion

09:00 – 09:50

IN FOCUS

Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies

Chairs:

Chiara Bucciarelli-Ducci, Cardiologist, London

Dimitrios Farmakis, Cardiologist, Athens

09:00 – 09:10

Clinical case

Carmen Labarta, Cardiologist, Madrid

09:10 – 09:20

ATTR cardiac amyloidosis: recent therapeutic advances

Peter van der Meer, Cardiologist, Groningen

09:20 – 09:30

AL cardiac amyloidosis: emerging treatment strategies and cardiac outcomes

Annamaria Brioli, Hematologist, Hannover

09:30 – 09:45

Discussion

09:45 – 10:30

GRACE PROJECT

Hybrid care in cardio-oncology: from promise to practice

Chairs:

Raúl Moreno, Cardiologist, Madrid

Teresa López Fernández, Cardiologist, Madrid

09:45 – 10:00

GRACE: a new model for hybrid care

Leandro Pecchia, Biomedical Engineer, Rome

10:00 – 10:10

Partnerships to co-create and implement healthcare innovation

María Mateos, Business Development Manager Medtronic Iberia

10:10 – 10:30

Hybrid care in cardio-oncology: are we ready and what do teams need?

Discussion pannel

Nieves Romero, Cardiologist, Sevilla

Oliver Higuera, Medical oncologist, Madrid

10:30 – 11:00

Coffee break

11:00 – 12:00

CLINICAL CASE FORUM

Vascular, valvular and metabolic challenges in patients with cancer

Chairs:

Pilar Zamora, Medical oncologist, Madrid

Victoria Delgado, Cardiologist, Barcelona

Antonia Sambola, Cardiologist, Barcelona

11:00 – 11:15

Fluoropyrimidine-associated chest pain: acute management and next steps

Cristina Contreras, Cardiologist, Madrid

11:15 – 11:30

Severe aortic stenosis in active cancer: timing TAVI and competing clinical priorities

Amparo Martínez Monzonis, Cardiologist, Santiago de Compostela

11:30 – 11:45

When anticoagulation leads to bleeding: what to do and when to act?

Cristina Pascual, Hematologist, Madrid

11:45 – 12:00

Obesity in cancer care: ignore or treat from day one?

Almudena Castro, Cardiologist, Madrid

12:00 – 12:50

FROM BENCH TO BEDSIDE

Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits

Chairs:

Cristina Mitroi, Cardiologist, Madrid

Álvaro Pinto, Medical oncologist, Madrid

12:00 – 12:10

CHIP as a cardiovascular risk modifier: what matters in cardio-oncology?

José Javier Fuster, Biochemist, Madrid

12:10 – 12:20

CHIP in lymphoma: biological links and implications for cardiac injury

Miguel Canales, Hematologist, Pamplona

12:20 – 12:30

TTN truncating variants before anthracycline therapy: proceed, modify or protect?

Juan Caro, Cardiologist, Madrid

12:30 – 12:40

Cardiomyopathy variants and cardiotoxicity: second hit or misdiagnosis

Rebeca Lorca, Cardiologist, Oviedo

12:40 – 12:50

Discussion

12:50 – 13:30

MEET THE EXPERTS

Anticipating and managing cardiovascular risk in patients with prostate and renal cancer

Chairs:

Álvaro Pinto, Medical oncologist, Madrid

Sergio Cinza, General practitioner, Santiago de Compostela

12:50 – 13:00

Cardiovascular adverse events with tyrosine-kinase inhibitors for renal cancer

Guillermo de Velasco, Medical oncologist, Madrid

13:00 – 13:10

Hormone therapy for prostate cancer and cardiovascular toxicity

Natalia Vidal, Medical oncologist, Madrid

13:10 – 13:20

Pre-treatment assessments in patients with prostate cancer

Estefanía Linares, Urologist, Madrid

13:20 – 13:30

Discussion

13:30 – 14:15

IN FOCUS

BTK inhibitors in CLL: new strategies, new cardiovascular questions

Chairs:

Raúl Córdoba, Hematologist, Madrid

Rebeca Lorca, Cardiologist, Oviedo

13:30 – 13:40

Real-world evidence: beyond clinical trials

Alicia Aguirre, Hematologist, Córdoba

13:40 – 13:50

Finite vs continuous treatment: cardiovascular risk after treatment discontinuation

Lucrecia Yáñez, Hematologist, Santander

13:50 – 14:00

Non-covalent BTK inhibitors: a new drug class with a favourable cardiovascular safety profile

José Ángel Hernández Rivas, Hematologist, Madrid

14:00 – 14:15

Discussion

14:15 – 16:00

Lunch break: Tutorials / Satellite Symposium

16:00 – 17:00

CLINICAL CASE FORUM

Prevention and permissive cardiotoxicity: are we doing too much or too little?

Chairs:

Vicente Pallarés, General practitioner, Castellón

Ana Martín, Cardiologist, Salamanca

16:00 – 16:15

Albuminuria during VEGF inhibition: marker or mandate to act

Pilar Mazón, Cardiologist, Santiago de Compostela

16:15 – 16:30

Permissive cardiotoxicity: LVEF-led or context-led decision-making?

Eduardo Zatarain, Cardiologist, Madrid

16:30 – 16:45

Myocardial injury in acute leukaemia: a triple-hit of host, disease, and treatment

Gabriela Rodríguez Macías, Hematologist, Madrid

16:45 – 17:00

CV surveillance after HSCT: defining who is truly high-risk

Irene Sánchez Vadillo, Hematologist, Madrid

CARDIOTOX 26

12-13 NOVEMBER
MADRID

VENUE Meeting Place Castellana 81, Madrid

17:00 – 17:45

SYMPOSIUM

Building the roadmap for the next generation of cardio-oncology care

Chairs:

Raúl Córdoba, Hematologist, Madrid

Teresa López-Fernández, Cardiologist, Madrid

17:00 – 17:15

Translational research priorities in cardio-oncology

Borja Ibáñez, Cardiologist, Madrid

17:15 – 17:30

Cardio-oncology roadmap: from trials and real-world data to future guidelines

Alexander Lyon, Cardiologist, London

17:30 – 17:45

Discussion

17:45 – 17:55

CLOSING REMARKS

CARDIOTOX 26

12-13 NOVEMBER
MADRID



Secretaría técnica

 **tactics**

 Barcelona · Madrid

 93 451 17 24

 info@tacticsmd.net

 www.tacticsmd.net